Introduction: Cardiovascular disease, primarily caused by atherosclerosis, is the leading cause of death worldwide. Previous studies show that inflammation plays a big role in all different stages of atherosclerosis. A previous clinical trial demonstrated that blocking inflammasome effects significantly reduced cardiovascular events, indicating that inflammasome suppression could be beneficial.
Aim: This study investigates how treatments with statins (atorvastatin, rosuvastatin), β- blockers (metoprolol), lutein, and cytokines (IL-18) affect inflammasome activities.
Method and Material: Blood samples from ten healthy individuals were used to isolate monocytes and neutrophils. Cells were stimulated with the aforementioned substances, and caspase-1 activity was measured as an indicator of inflammasome activation.
Results & Discussion: Monocytes have higher intrinsic and stimulated inflammasome activity compared to neutrophils. Statins increased caspase-1 activity in partially activated monocytes, suggesting a potential pro-inflammatory effect in monocytes. There was a significant decrease of caspase-1 activity when the monocytes were treated with metoprolol underlining a potential anti-inflammatory mechanism of β-blockers in monocytes.
Conclusion: These findings highlight the potential effects of statins and metoprolol on inflammation and the need for further research on their impact on cardiovascular disease.